权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Studies of the expression of encogenes and superoxide dismutase (SOD) in human malignant brain tumors.

人恶性脑肿瘤中内基因和超氧化物歧化酶（SOD）表达的研究。

基本信息

批准号：
07671526
负责人：
KURISAKA Masahiro
金额：
$ 0.96万
依托单位：
Kochi Medical School
依托单位国家：
日本
项目类别：
Grant-in-Aid for Scientific Research (C)
财政年份：
1995
资助国家：
日本
起止时间：
1995 至 1996
项目状态：
已结题

来源：
https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-07671526/
关键词：
Brain tumor Free radical Catalase Superoxide dismutase Immunohistochemistry

项目摘要

We have reported the data of free radical, catalase and superoxide dismutase (SOD) in human brain tumors, and we measured them again in much more volume of brain tumor tissues. However, the data did not indicate the difference between malignant and benign tumors or the prognosis of the patients with brain tumor.Recently, we published the cell culture of glioblastoma which obtain from a young female. Now weare studying to see the expression of SOD in the cell culture medium following the administration of anti cancer agents and/or irradiation to the culture cell in invitro.The expression of SOD in human malignant brain tumors such as anaplastic astrocytomas, glioblastomas medulloblastomas and metastatic tumors, and in human benign brain tumors such as meningiomas, pituitary adenomas and schwannomas which done using an immunohistochemical technique. In general, the expression of SOD was lower in malignant brain tumors than benign tumors. However, higher expression of SOD in malignant brain tumors observed only in recurrent cases. Therefore poor outcome of the patients with malignant brain tumor, may not depend on the positivity of SOD immunostain, due to it's biological behavior.A focused in malignant brain tumors, better outcome was observed in lower positivity of SOD immunostain and worse outcome in higher positivity. Thus, the measurement of SOD in malignant brain tumors was a good indicator to asses the prognosis of the patients. On the other hand, the outcome of the patients with benign brain tumors was much correlate to the degree of tumor removal than the positivity of SOD in the tumor tissues.The resistancy of malignant brain tumors to the adjuvant therapies is due to the inadequate or imcomplete chemotherapy and/or radiotherapy. Our next study will be focused to this point and will able to make an effective therapeutic strategy to prevent resistency in the adjuvant therapies.

本文报道了人脑肿瘤组织中自由基、过氧化氢酶和超氧化物歧化酶（SOD）的测定结果，并在更大体积的脑肿瘤组织中进行了测定。然而，这些数据并没有表明恶性和良性肿瘤之间的差异或脑肿瘤患者的预后。最近，我们发表了一个年轻女性胶质母细胞瘤的细胞培养。本研究采用免疫组织化学方法，观察了SOD在人脑恶性肿瘤（如间变性星形细胞瘤、胶质母细胞瘤、髓母细胞瘤、转移瘤）和脑良性肿瘤（如脑膜瘤、垂体腺瘤、神经鞘瘤）中的表达。恶性脑肿瘤中SOD的表达普遍低于良性脑肿瘤。而SOD在恶性脑肿瘤中的高表达仅见于复发病例。因此，恶性脑肿瘤患者预后不良，可能与SOD免疫染色阳性无关，这是由于其生物学行为所致。在恶性脑肿瘤中，SOD免疫染色阳性率低者预后较好，阳性率高者预后较差。因此，测定恶性脑肿瘤患者血清SOD水平可作为判断患者预后的良好指标。良性脑肿瘤患者的预后与肿瘤切除程度有关，而与肿瘤组织中SOD阳性无关，恶性脑肿瘤对辅助治疗的抵抗主要是由于化疗和/或放疗不充分或不彻底。我们下一步的研究将集中在这一点上，并将能够制定有效的治疗策略，以防止在辅助治疗中的复发。